Clinical Disorders of Hyperkalemia

Seldin and Giebisch's The Kidney

Volumn , Issue , 2008, Pages 1387-1405

  Kamel, Kamel S ^a   Lin, Shih Hua ^a   Halperin, Mitchell L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882882217     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088488-9.50052-8     Document Type: Chapter

References (118)

1. Adrogue H.J., Madias N.E. Changes in plasma potassium concentration during acute acidbase disturbances. Am J Med 1981, 71:456-467.
2. Allon M., Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int 1990, 38:869-872.
3. Allon M., Dunlay R., Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann Intern Med 1989, 110:426-429.
4. Allon M., Shanklin N. Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. Am J Kidney Dis 1996, 28:508-514.
5. Alper S. The band 3-related anion exchanger (AE) gene family. Ann Rev Physiol 1991, 53:549-564.
6. Arrambide K., Toto R.D. Tumor lysis syndrome. Sem Nephrol 1993, 13:273-280.
7. Backman K.A., Hayslett J.P. Role of the medullary collecting duct in potassium conservation. Pflugers Arch 1983, 396:297-300.
8. Bakris G.L., et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int 1900, 58:2084.
9. Baltazar R.F., Mower M.M., Reider R., Funk M., Salomon J. Acute fluoride poisoning leading 000to fatal hyperkalemia. Chest 1980, 78:660-663.
10. Bercovici M., Chen C., Goldstein M., Stinebaugh B., Halperin M. Effect of acute changes in the PaCO2 on acid-base parameters in normal dogs and dogs with metabolic acidosis or alkalosis. Can J Physiol Pharmacol 1983, 61:166-173.
11. Blumberg A., Weidmann P., Ferrari P. Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. Kidney Int 1992, 41:369-374.
12. Blumberg A., Weidmann P., Shaw S., Gnadinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med 1988, 85:507-512.
13. Bonny O., Rossier B.C. Disturbances of Na/K balance: Pseudohypoaldosteronism revisted. J Am Soc Nephrol 2002, 13:2399-2414.
14. Bushinsky D.A., Gennari F.J. Life-threatening hyperkalemia induced by arginine. Ann Int Med 1978, 89:632-634.
15. Canova C.R., et al. Effect of low molecular weight heparin on serum potassium. Lancet 1997, 349:1447.
16. Carlisle E.J.F., Donnelly S.M., Ethier J., Quaggin S.E., Kaiser U., Vasuvattakul S., Kamel K.S., Halperin M.L. Modulation of the secretion of potassium by accompanying anions in humans. Kidney Int 1991, 39:1206-1212.
17. Cheema-Dhadli S., Lin S.-H., Chong C.K., Kamel K.S., Halperin M.L. Requirements for a high rate of potassium excretion in rats consuming a low electrolyte diet. J Physiol 1906, 572:493-501.
18. Choi M.J., Fernandez P.C., Patnaik A., Coupaye-Gerard B., D'Andrea D., Zerlip H., Kleyman T.R. Trimethoprim induced hyperkalemia in a patient with AIDS. N Engl J Med 1993, 328:703-706.
19. + transport in skeletal muscle. Physiol Rev 1986, 66:542-580.
20. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
21. Conway M.J., Seibel J.A., Eaton R.P. Thyrotoxicosis and hypokalemic periodic paralysis: Improvement with beta blockade. Ann Int Med 1974, 81:332-336.
22. + exchanger gene family: their structure, function, expression, and regulation. The Kidney: Physiology & Pathophysiology 1900, 223-234. Lippincott Williams & Wilkins, Philadelphia. D.W. Seldin, G. Giebisch (Eds.).
23. Davids M.R., Edoute Y., Jungas R.L., Halperin M.L. Facilitating an understanding of integrative physiology: Emphasis on the compositon of body fluid compartments. Can J Physiol Pharmacol 2002, 80:835-850.
24. DeFronzo R.A., Bia M., Birkhead G. Epinephrine and potassiun homeostasis. Kidney Int 1981, 20:83.
25. DeFronzo R.A., Sherwin R.S., Dillingham M., Hendler R., Tamborlane W.V., Felig P. Influence of basal insulin and glucagon secretion on potassium and sodium metabolism: studies with somatostatin. J Clin Invest 1978, 61:472-479.
26. DeMars C., Hollister K., Tomassoni A., Himmelfarb J., Halperin M.L. Citric acidosis: A lifethreatening cause of metabolic acidosis. Ann Emerg Med 2001, 38:588-591.
27. Dickerman H.W., Walker W.G. Effect of cationic amino acid infusion on potassium metabolism in vivo. Am J Physiol 1964, 206:403-408.
28. Don B.R., Sebastian A., Cheitlin M., Christiansen M., Schambelan M. Pseudohyperkalemia caused by fist clenching during phlebotomy. N Engl J Med 1990, 322:1290-1292.
29. Emmett M., Hootkins R.E., Fine K.D. Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion. Gastroenterology 1995, 108:752-760.
30. Ethier J.H., Honrath U., Veress A., Sonnenberg H., Halperin M.L. Nephron site responsible for the reduced kaliuretic response to mineralocorticoids during hypokalemia in rats. Kidney Int 1990, 38:812-817.
31. Ethier J.H., Kamel K.S., Magner P.O., Lemann J.J., Halperin M.L. The transtubular potassium concentration in patients with hypokalemia and hyperkalemia. Am J Kidney Dis 1990, 15:309-315.
32. Farman N., Boulkroun S., Courtois-Coutry N. SGK: an old enzyme revisited. J Clin Invest 2002, 110:1233-1234.
33. Field M. Intestinal transport and the pathophysiology of diarrhea. J Clin Invest 1903, 111:931-943.
34. Field M.J., Giebisch G.J. Hormonal control of renal potassium excretion. Kidney Int 1985, 27:379-387.
35. Flores S.Y., Debonneville C., Staub O. The role of Nedd4/Nedd4-like dependant ubiquitylation in epithelial transport processes. Pflugers Arch 2003, 446:334-338.
36. Fontaine B., Khurana T.S., Hoffman E.P., et al. Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene. Science 1990, 250:1000-1002.
37. Gagnon R.F., Halperin M.L. Possible mechanisms to explain the absence of hyperkalemia in a patient with Addison's disease. Nephrol Dial Transplant 2001, 16:1280-1284.
38. + channel by aldosterone: Open questions and emerging answers. Kidney Int 2000, 57:1270-1276.
39. Giebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol 1998, 274:F817-F833.
40. Greenberg S., Reiser I.W., Chou S.-Y., Porush J.G. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993, 119:291-295.
41. Gronert G.A., Theye R.A. Pathophysiology of hyperkalemia induced by succinylcholine. Anesthesiology 1975, 43:89-99.
42. Gruy-Kapral C., Emmett M., Santa Ana C.A. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol 1998, 9:1924-1930.
43. Guttierez R., Schlessinger F., Oster J.R., Rietberg B., Perez G.O. Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal disease. Miner Electrolyte Metab 1991, 17:297-302.
44. Halperin M.L., Kamel K.S. Potassium. Lancet 1998, 352:135-142.
45. Halperin M.L. The ACID Truth and BASIC Facts-With a Sweet Touch, an enLYTEnment 2004, RossMark Medical Publishers, Toronto. 5th ed.
46. Harris R.Z. Cyclooxygenase-2 in the kidney. J Am Soc Nephrol 2000, 42:2387-2394.
47. Iolascon A., Stewart G.W., Ajetunmobi J.F., Perrotta S., Delaunay J., Carella M., Zelante L., Gasparini P. Familial pseudohyperkalemia maps to the same locus as dehydrated hereditary stomatocytosis (hereditary xerocytosis). Blood 1999, 93:3120-3123.
48. Iwashita K., Kitamura K., Narikiyo T., Adachi M., Shiraishi N., Miyoshi T., Nagano J., Tuyendo G., Nonoguchi H., Tomita K. Inhibition of prostasin secretion by serine protease inhibitors in the kidney. J Am Soc Nephrol 2003, 14:11-16.
49. +channels in an open conformation. Nature 2004, 430:806-810.
50. Juel C., Halestrap A.P. Lactate transport in skeletal muscle-role and regulation of the monocarboxylate transporter. J Physiol 1999, 517:633-642.
51. Juurlink D.N., Mamdani M.M., Lee D.S., Kopp A., Austin P.C., Laupacis A., Redelmeier D.A. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543-551.
52. Kamel K., Ethier J.H., Quaggin S., Levin A., Albert S., Carlisle E.J.F., Halperin M.L. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporin. J Am Soc Nephrol 1992, 2:1279-1284.
53. Kamel K.S., Quaggin S., Scheich A., Halperin M.L. Disorders of potassium homeostasis: an approach based on pathophysiology. Am J Kidney Dis 1994, 24:597-613.
54. Kamel K.S., Wei C. Controversial issues in treatment of hyperkalemia. Nephrol Dialysis Transpl 2003, 18:2215-2218.
55. Kemper M.J., Harps E., Muller-Wiefel D.E. Hyperkalemia: therapeutic options in acute and chronic renal failure. Clin Nephrol 1995, 46:67-69.
56. Kifor I., et al. Potassium stimulated angiotensin release from adrenal capsules and enzymatically digested cells of the zona gloerulosa. Endocrinology 1991, 129:823.
57. Kim H.J. Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients. Nephron 1996, 72:476-482.
58. Kitagawa H., Chang H., Fujita T. Hyperkalemia due to nafamostat mesylate. N Engl J Med 1995, 332:687.
59. Lens X.M., Montoliu J., Cases A., Campistol J.M., Revert L. Treatment of hyperkalemia in renal failure: salbutamol v. insulin. Nephrol Dial Transplant 1989, 4:228-232.
60. Lin D.H., Sterling H., Yang B., Hebert S.C., Giebisch G., Wang W.H. Protein tyrosine kinase is expressed and regulates ROMK1 location in the cortical collecting duct. Am J Physiol 2004, 286:F881-F892.
61. Lin S.H., Hsu Y.-J., Chiu J.-S., Chu S.-J., Davids M.R., Halperin M.L. Osmotic demyelination syndrome: A potentially avoidable disaster. Q J Med 1903, 96:935-947.
62. Lin S.H0, Lin Y.F. Propranolol rapidly reverses paralysis, hypokalemia and hypophosphatemia in thyrotoxic periodic paralysis. Am J Kidney Dis 2001, 37:620-624.
63. Liou H.H., Chiang S.S., Wu S.C., et al. Hypokalemic effects of intravenous infusion or nebulization of salbutamol in patients with chronic renal failure. Am J Kidney Dis 1994, 23:266-270.
64. Mandelberg A., Krupnik Z., Houri S. Salbutamol metered-dose inhaler with spacer for hyperkalemia: how fast? how safe?. Chest 1999, 115:617-622.
65. Mayan H., Vered I., Mouallem M., Tzadok-Witkon M., Pauzner R., Farfel Z. Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrinol Metab 2002, 87:3248-3254.
66. McIvor M.E., Cummings C.E., Mower M.M., Wenk R.E., Lustgarten J.A., Baltazar R.F., Salomon J. Sudden cardiac death from acute fluoride intoxication: the role of potassium. Ann Emerg Med 1987, 16:777-781.
67. McKechnie J.K., Leary W.P., Joubert S.M. Some electrocardiographic and biochemical changes recorded in marathon runners. S Afr Med J 1967, 41:722-725.
68. Montoliu J., Almirall J., Ponz E., Campistol J.M., Revert L. Treatment of hyperkalemia in renal failure with salbutamol inhalation. J Intern Med 1990, 228:35-37.
69. Montoliu J., Lens X.M., Revert L. Potassium-lowering effect of albuterol for hyperkalemia in renal failure. Arch Intern Med 1987, 147:713-717.
70. Moore R.D. Stimulation of Na:H exchange by insulin. Biophys J 1981, 33:203-210.
71. Mueller B.A., Scott M.K., Sowinski K.M., Prag K.A. Noni juice (morinda citrifolia): Hidden potential for hyperkalemia?. Am J Kidney Dis 2000, 35:310-312.
72. + transport properties in the rabbit cortical collecting duct. Br J Pharmacol 1994, 111:173-178.
73. Orringer C.E., Eustace J.C., Wunsch C.D., Gardner L.B. Natural history of lactic acidosis after Grand-Mal seizures. N Engl J Med 1977, 297:796-799.
74. Orth D.N., Kovacs W.J. The adrenal cortex. Williams Textbook of Endocrinology 1998, 550. WB Saunders, Philadelpha. 9th ed. J.D. Wilson, D.W. Foster, H.M. Kronenberg, P.R. Larsen (Eds.).
75. Oster J.R., Singer I., Fisherman L.M. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995, 98:575-586.
76. Palmer B.F. Managing hyperkalemia caused by inhibitors of the renin-angiotensionaldosterone system. N Engl J Med 2004, 351:585-592.
77. Palmer L., Antonian J., Frindt G. Regulation of the apical K and Na channels and Na/K pumps in the rat cortical collecting tubule by dietary K. J Gen Physiol 1994, 105:693-710.
78. Palmer L., Frindt G. Regulation of the apical K channels in the rat cortical collecting tubule during changes in K intake. Am J Physiol 1999, 277:F805-F812.
79. Perazella M.A., Biswas P. Acute hyperkalemia associated with intravenous epsilonaminocaproic acid therapy. Am J Kidney Dis 1999, 33:782-785.
80. Phelps K.R., Lieberman R.L., Oh M.S., Carroll H.J. Pathophysiology of the syndrome of hyporeninemic hypoaldosteronism. Metabolism 1980, 29:186-199.
81. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R.S.H., Kleiman J., Gatlin M. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1903, 348:1309-1321.
82. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
83. Porte D.J. Sympathetic regulation of insulin secretion. Arch Intern Med 1969, 123:252-260.
84. Raff H. Glucocorticoid inhibition of neurohypophysial vasopressin secretion. Am J Physiol 1987, 252:R635-R644.
85. Rosa R.M., Silva P., Young J.B., Landsberg L., Brown R.S., Rowe J.W., Epstein F.H. Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 1980, 302:431-434.
86. Rosa R.M., Williams M.E., Epstein F.H. Extrarenal potassium metabolism. The Kidney: Physiology and Pathophysiology 1992, 2165-2190. Raven Press, New York. 2nd ed. D.W. Seldin, G. Giebisch (Eds.).
87. Schambelan M., Sebastian A., Rector F.C. Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): Role of increased renal chloride reabsorption. Kidney Int 1981, 19:716-727.
88. Schild L. The ENaC channel as the primary determinant of two human diseases: Liddle's syndrome and pseudohypoaldosteronism. Neprhologie 1996, 17:395-400.
89. Schreiber M., Halperin M.L. Urea excretion rate as a contributor to trimethoprim-induced hyperkalemia. Ann Int Med 1994, 120:166-167.
90. Schreiber M.S., Chen C.-B., Lessan-Pezeshki M., Halperin M.L., Schlanger L.E., Patnaik A., Ling B.N., Kleyman T.R. Antikaliuretic action of trimethoprim is minimized by raising urine pH. Kidney Int 1996, 49:82-87.
91. Sebastian A., McSherry E., Morris R.C. Renal potassium wasting in renal tubular acidosis (RTA): its occurrence in types 1 and 2 RTA despite sustained correction of systemic acidosis. J Clin Invest 1971, 50:667-678.
92. Shafiee M.A., Bohn D., Hoorn E.J., Halperin M.L. How to select optimal maintenance intravenous fluid therapy. Q J Med 2003, 96:601-610.
93. Sherman R.A., et al. Suppression of aldosterone production by low-dose heparin. Am J Nephrol 1986, 6:165.
94. Siebels M., Andrassy K., Vecsei P., Seelig H.P., Back T., Nawroth P., Weber E. Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions. Thromb Res 1992, 66:467-473.
95. Smith T.W., Willerson J.T. Suicidal and accidental digoxin ingestion. Report of five cases with serum digoxin level correlations. Circulation 1971, 44:29-36.
96. Steele A., deVeber H., Quaggin S.E., Scheich A., Ethier J., Halperin M.L. What is responsible for the diurnal variation in potassium excretion. Am J Physiol 1994, 36:R554-R560.
97. Sterns R.H., Guzzo J., Feig P.U., Singer I. Internal potassium balance and the control of the plasma potassium concentration. Medicine 1981, 60:339-354.
98. Stokes J.B. Ion transport by the collecting duct. Sem Nephrol 1993, 13:202-212.
99. Su M., Chu J., Howland M.A., Nelson L.S., Hoffman R.S. Amiodarone attenuates fluoride-induced hyperkalemia in vitro. Acad Emerg Med 1903, 10:105-109.
100. Swan R.C., Pitts R.F. Neutralization of infused acid by nephrectomized dogs. J Clin Invest 1955, 34:205-212.
101. Talbott J.H., Schwab R.S. Recent advances in the biochemistry and therapeutics of potassium salts. N Engl J Med 1940, 222:585-590.
102. Textor S.C., Bravo E.L., Tarazi R.C. Hyperkalemia in azotemic patients during angiotensinconverting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982, 158:26-32.
103. Tucker W.S.J., Snell B.B., Island D.P., Gregg C.R. Reversible adrenal insufficiency induced by ketoconazole. JAMA 1985, 253:2413-2414.
104. Vallon V., Lang F. New insights into the role of serum- and glucocorticoid-inducible kinase SGK1 in the regulation of renal function and blood pressure. J Am Soc Nephrol 2005, 14:59-66.
105. van Buren M., Rabelink T.J., van Rijn H.J.M., Koomans H.A. Effects of acute NaCl, KCl and KHCO3 loads on renal electrolyte excretion in humans. Clin Sci 1992, 83:567-574.
106. Velazquez H., Perazella M.A., Wright F.S., Ellison D.H. Renal mechanism of trimethopriminduced hyperkalemia. Ann Intern Med 1993, 119:295-301.
107. Velazquez H., Wright F.S., Good D.W. Luminal influences on potassium secretion: chloride replacement with sulfate. Am J Physiol 1982, 242:F46-F55.
108. Vuagniaux G., Vallet V., Jaeger N.F., Hummler E., Rossier B.C. Synergistic activation of ENaC by three membrane-bound channel-activating serine proteases (mCAP1, mCAP2, and mCAP3) and serum- and glucocorticoid-regulated kinase (Sgk1) in Xenopus oocytes. J Gen Physiol 1902, 120:191-201.
109. Waldegger S., Jentsch T.J. From tonus to tonicity: physiology of CIC chloride channels. J Am Soc Nephrol 2000, 11:1331-1339.
110. + channels. The Kidney: Physiology & Pathophysiology 1900, 235-249. Lippincott Williams & Wilkins, Philadelphia. D.W. ]Seldin (Ed.).
111. Wang W.H. Regulation of renal K transport by dietary K intake. Annu Rev Physiol 2004, 66:547-569.
112. White P.C., Speiser P.W. Congenital adrenal hyperplasia. Endocrine Rev 2000, 21:245-291.
113. White P.C. Disorders of aldosterone biosynthesis and action. Mol Cell Endocrinol 2004, 217:81-87.
114. Williams M.E., Gervino E.V., Rosa R.M., Landsberg L., Young J.B., Silva P., Epstein F.H. Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med 1985, 312:823-827.
115. Wilson F.H., Disse-Nocodeme S., Choate K.A., Ishikawa K., Nelson-Williams C., Desitter I., et al. Human hypertension caused by mutations in WNK kinases. Science 2001, 293:1107-1112.
116. Woolf A.D., Wenger T., Smith T.W., Lovejoy F.H.J. The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. N Engl J Med 1992, 326:1739-1744.
117. Yang C.-L., Angell J., Mitchell R., Ellison D.H. WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest 2003, 111:1039-1045.
118. Zierler K.L., Rabinowitz D. Effect of very small concentrations of insulin on forearm metabolism: persistence of its action on potassium and free fatty acids without its effect on glucose. J Clin Invest 1963, 43:950-962.